South Africa implemented Universal Test-and-Treat (UTT) in Sept 2016, extending eligibility for antiretroviral therapy (ART) to all people with HIV, regardless of CD4 count. However, the impact of UTT will be limited if people do not seek care early in infection.
We constructed a national HIV cohort by linking the complete historical laboratory records of South Africa’s public sector HIV program, Apr 2004 – Mar 2018, enabling all patients to be tracked longitudinally. For each patient, we defined “CD4 at presentation” as first CD4 count in the database and “CD4 at ART start” as the first CD4 count within 90 days of ART workup (ALT/HG/CRT) taken in advance of starting ART. (The same CD4 count would apply for each if a patient started ART at presentation.) We assessed the distribution of CD4 counts at presentation and at ART start in 2015 (pre-UTT) and 2017 (post-UTT) and assessed features of these distributions (e.g. median) over time, 2004-2018. We also estimated trends in numbers of patients entering care and starting ART (as proxied by a VL or ART workup) at different CD4 counts, and evaluated the impact of ART eligibility expansions (from <200 to <350, to <500, and to UTT) on these trends.
12M patients had a first CD4 count through March 2018. In 2017, 48.2% of patients presented with CD4 >=350 cells/mm3, and just 29.3% presented with CD4 counts >=500 (newly-eligible with UTT) (Fig 1a). The shares were nearly identical in 2015 (pre-UTT): 48.3% >=350 and 28.8% >=500. Median CD4 at presentation increased from 229 cells/mm3 in 2005 to 338 in 2015, but plateaued thereafter, reaching only 337 in 2017 (Fig 1b). Median CD4 at ART start increased from 173 cells/mm3 in 2005 to 327 in 2015, with a marginal increase to 332 in 2017. With each ART eligibility expansion, the gap between median CD4 at presentation and ART start narrowed, disappearing under UTT (Fig 1b). Numbers seeking care did not increase with UTT. Although ART eligibility expansions led to short-run increases in numbers starting ART, each successive change in CD4 criteria affected a smaller share of patients, and as a result, the numbers starting ART have plateaued since 2011 (Fig 1c).
UTT has not led to an increase in early care-seeking, with most patients still presenting with CD4<350. The impact of UTT on numbers starting ART has been limited by late presentation in South Africa.